The Costs of Cancer 2020 Edition Cancer Action Network SM

Total Page:16

File Type:pdf, Size:1020Kb

The Costs of Cancer 2020 Edition Cancer Action Network SM Cancer Action Network SM The Costs of Cancer 2020 Edition Cancer Action Network SM The American Cancer Society Cancer Action NetworkSM (ACS CAN) is making cancer—and the affordability of cancer care—a top priority for public officials and candidates at the federal, state and local levels. ACS CAN is the American Cancer Society’s nonprofit, nonpartisan advocacy affiliate. ACS CAN empowers advocates across the country to make their voices heard and influence evidence-based public policy change, as well as legislative and regulatory solutions that will reduce the cancer burden. This ACS CAN report focuses specifically on the costs of cancer borne by patients in active cancer treatment as well as cancer survivors. It examines the factors contributing to the cost of cancer care, the types of direct costs patients face and the indirect costs associated with cancer. To more fully illustrate what people with cancer actually pay for care, the report also presents scenario models for several types of cancer and different types of insurance coverage. Finally, the report presents public policy recommendations for making cancer treatments more affordable for patients, survivors and the health care system as a whole. Published October 2020 For more information regarding the methodology of the modeled patient cost scenarios in this report, and to view additional materials related to this report, please visit www.fightcancer.org/costsofcancer. This report was supported in part by grants from the Association for Accessible Medicines and its Biosimilars Council, AbbVie, the Biotechnology Innovation Organization, Boehringer Ingelheim, Foundation Medicine, Janssen, Merck, Mylan, Pfizer, Sandoz and Sanofi. 2 American Cancer Society Cancer Action Network The Costs of Cancer 2020 Introduction The American Cancer Society (ACS) estimates that roughly 1.8 million new cases of cancer will be diagnosed in the U.S. in 2020 and that more than 16.9 million Americans living today have a cancer history.1 As a leading cause of death and disease in the U.S., not only does cancer take an enormous toll on the health of patients and survivors—it also has a tremendous financial impact. Patient Costs are Unaffordable Everyone Pays the Costs of For patients and their families, the costs Cancer Treatment associated with direct cancer care are staggering. Patient Out-of-Pocket In 2018 cancer patients in the U.S. paid $5.6 Costs = $5.6 billion 2 billion out of pocket for cancer treatments, Medicaid 5% including surgical procedures, radiation 10% 4% Other treatments and chemotherapy drugs. Overall Cancer Costs are Rising Cancer also represents a significant portion of total U.S. health care spending. Approximately $183 billion was spent in the U.S. on cancer- 33% related health care in 2015, and this amount is Medicare projected to grow to $246 billion by 2030—an increase of 34%. 49% Private These high costs are paid by people with Insurance cancer and their families, employers, insurance companies and taxpayer-funded public programs Source: Data retrieved from the Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey, 2018. https://meps.ahrq.gov/mepsweb/ like Medicare and Medicaid. *See reference for category definitions.3 Percentages in chart have been rounded. National Cancer Costs Projected to Increase Drastically by 2030 $ 250 B 34% increase $245.6B $ 200 B $222.2B $200.7B $182.6B $ 150 B $ 100 B $ 50 B $ 0 B 2015 2020 2025 2030 Spending on Cancer Care—in 2019 billions of dollars Source: Mariotto AB, Enewold L, Zhao J, Zeruto CA, Yabroff KR. Medical Care Costs Associated with Cancer Survivorship in the United States. Cancer Epidemiol Biomarkers Prev June 10 2020 DOI: 10.1158/1055-9965.EPI-19-1534 American Cancer Society Cancer Action Network The Costs of Cancer 2020 3 The Costs of Cancer Do Not Impact The Costs of Cancer Disparities All Patients Equally Cancer and its costs do not impact all Because of high costs, many people with cancer individuals equally. Look for information about and those who have survived cancer experience The Costs of Cancer Disparities throughout financial hardship, including problems paying bills, this report. depletion of savings, delaying or skipping needed medical care, and potential bankruptcy. These costs and hardships do not impact all cancer patients equally—there are certain factors that make a patient more likely to experience financial hardship: Cancer patients are more likely to experience financial hardship if they are: Younger People of Color 70% 70% 60% 60% 63.5% 58.9% 50% 50% 50.9% 48.5% 40% 40% 30% 30% 20% 20% 10% 10% 0% 0% Ages 18-54 Ages 55-64 Other Races/ Non-Hispanic Whites Ethnicities Less Educated Lower Income 70% 70% 69.5% 60% 60% 60.0% 60.5% 50% 50% 52.1% 51.8% 40% 40% 47.2% 30% 30% 20% 20% 10% 10% 0% 0% Less than high High school Some college or Low-income Middle-income High-income school graduate graduate more (≤138% FPL) (139-400%FPL) (>400% FPL) % of Individuals with a History of Cancer Reporting at least 1 Ty pe of Financial Hardship, Ages 18-64 *FPL = Federal Poverty Level Source: Han X, Zhao J, Zheng Z, de Moor JS, Virgo KS, Yabroff KR. Medical Financial Hardship Intensity and Financial Sacrifice Associated with Cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2020;29(2):308-317. doi:10.1158/1055-9965.EPI-19-0460 Note that similar patterns of disparities exist in the over-65 population. 4 American Cancer Society Cancer Action Network The Costs of Cancer 2020 Factors Contributing to the Costs of Cancer With more than 200 different types of cancer, there is no “one size fits all” cancer treatment—and therefore the costs of cancer treatment vary significantly from patient to patient. However, there are several consistent factors that contribute to patients’ overall costs for their care. Insurance Status/Type of Insurance Coverage: Survivor Views: The Costs of Cancer in Patients without health insurance are responsible Their Own Words for all of their treatment costs. Some uninsured “I had good insurance through my husband’s patients may qualify for “charity care,” may be able work, but our deductibles were always to participate in drug discount programs to reduce high. We met our deductible twice with my their costs or may be able to negotiate discounts cancers, we have never met it otherwise. with providers. For patients with insurance, the The benefits after meeting the deductible kind of health insurance the patient has and were nice, but we had to put all of our bills the design of their plan are some of the most on payment plans and most would go into important factors in determining the ultimate costs collections even though we were paying for patients. Patient costs are often referred to them. When you are paying 8 different bills as cost sharing or an out-of-pocket requirement. for thousands of dollars, and one person is Following are some of the out-of-pocket working with the cost of living and food, there is little to go around.” components that determine what patients pay: Ovarian Cancer Survivor, Ohio ■ Premium: The monthly amount the patient pays to stay covered by the insurance plan (in plans with a deductible of $1,400 or higher some cases an employer pays all or part of a for individuals or $2,800 for families—are patient’s premiums). Premiums are determined becoming more prevalent in the U.S.4 by a number of factors that differ depending ■ Co-payment or Co-pay: A flat fee patients on type of insurance and can include: age of pay per health care service, procedure or the enrollee, where the enrollee lives, how prescription. generous the benefits are (including cost- sharing amounts listed below) and how much ■ Co-insurance: A percentage patients pay the plan anticipates it will pay in health care of the total cost of a prescription, service or claims for enrollees. While many enrollees focus procedure. Co-insurance can be unpredictable only on premium prices, the other out-of-pocket because the patient often cannot determine the costs listed below offer a total cost of the treatment until arriving at the Current law requires many private more complete picture of pharmacy or receiving a bill after the treatment. what patients ultimately pay. ■ Out-of-Pocket Maximum or Out-of-Pocket insurance plans to limit annual patient For instance, enrollees who Cap: The limit on what a patient must pay each are high utilizers of care— year before the health plan starts to pay 100% out-of-pocket spending. The 2020 limit including those with cancer— for covered, in-network benefits. This amount is $8,150 for an individual plan and often face a trade-off of excludes premiums. Current law establishes higher premiums for lower these caps in most private insurance plans. $16,300 for a family plan. out-of-pocket costs and vice Caps provide a crucial protection to patients versa. with high health care costs. ■ Deductible: The amount the patient must first ■ In-Network vs. Out-of-Network: Many health pay out of pocket for care before the insurance insurance plans have “networks” of doctors, plan will start covering costs. Some plans have hospitals, and pharmacies. If a patient goes to separate deductibles for medical services, an “in-network” provider, cost sharing is usually drugs, and/or out-of-network services. High lower because the insurer has negotiated deductible health plans—defined in 2020 as rates with the provider. Some insurance plans American Cancer Society Cancer Action Network The Costs of Cancer 2020 5 charge more cost sharing for “out-of-network” Other factors contributing to providers, while other plans do not cover out-of- network providers at all.
Recommended publications
  • Medical Oncology and Breast Cancer
    The Breast Center Smilow Cancer Hospital 20 York Street, North Pavilion New Haven, CT 06510 Phone: (203) 200-2328 Fax: (203) 200-2075 MEDICAL ONCOLOGY Treatment for breast cancer is multidisciplinary. The primary physicians with whom you may meet as part of your care are the medical oncologist, the breast surgeon, and often the radiation oncologist. A list of these specialty physicians will be provided to you. Each provider works with a team of caregivers to ensure that every patient receives high quality, personalized, breast cancer care. The medical oncologist specializes in “systemic therapy”, or medications that treat the whole body. For women with early stage breast cancer, systemic therapy is often recommended to provide the best opportunity to prevent breast cancer from returning. SYSTEMIC THERAPY Depending on the specific characteristics of your cancer, your medical oncologist may prescribe systemic therapy. Systemic therapy can be hormone pills, IV chemotherapy, antibody therapy (also called “immunotherapy”), and oral chemotherapy; sometimes patients receive more than one type of systemic therapy. Systemic therapy can happen before surgery (called “neoadjuvant therapy”) or after surgery (“adjuvant therapy”). If appropriate, your breast surgeon and medical oncologist will discuss the benefits of neoadjuvant and adjuvant therapy with you. As a National Comprehensive Cancer Network (NCCN) Member Institution, we are dedicated to following the treatment guidelines that have been shown to be most effective. We also have a variety of clinical trials that will help us find better ways to treat breast cancer. Your medical oncologist will recommend what treatment types and regimens are best for you. The information used to make these decisions include: the location of the cancer, the size of the cancer, the type of cancer, whether the cancer is invasive, the grade of the cancer (a measure of its aggressiveness), prognostic factors such as hormone receptors and HER2 status, and lymph node involvement.
    [Show full text]
  • Exposure to Carcinogens and Work-Related Cancer: a Review of Assessment Methods
    European Agency for Safety and Health at Work ISSN: 1831-9343 Exposure to carcinogens and work-related cancer: A review of assessment methods European Risk Observatory Report Exposure to carcinogens and work-related cancer: A review of assessment measures Authors: Dr Lothar Lißner, Kooperationsstelle Hamburg IFE GmbH Mr Klaus Kuhl (task leader), Kooperationsstelle Hamburg IFE GmbH Dr Timo Kauppinen, Finnish Institute of Occupational Health Ms Sanni Uuksulainen, Finnish Institute of Occupational Health Cross-checker: Professor Ulla B. Vogel from the National Working Environment Research Centre in Denmark Project management: Dr Elke Schneider - European Agency for Safety and Health at Work (EU-OSHA) Europe Direct is a service to help you find answers to your questions about the European Union Freephone number (*): 00 800 6 7 8 9 10 11 (*) Certain mobile telephone operators do not allow access to 00 800 numbers, or these calls may be billed. More information on the European Union is available on the Internet ( 48TU http://europa.euU48T). Cataloguing data can be found on the cover of this publication. Luxembourg: Publications Office of the European Union, 2014 ISBN: 978-92-9240-500-7 doi: 10.2802/33336 Cover pictures: (clockwise): Anthony Jay Villalon (Fotolia); ©Roman Milert (Fotolia); ©Simona Palijanskaite; ©Kari Rissa © European Agency for Safety and Health at Work, 2014 Reproduction is authorised provided the source is acknowledged. European Agency for Safety and Health at Work – EU-OSHA 1 Exposure to carcinogens and work-related cancer:
    [Show full text]
  • About Ovarian Cancer Overview and Types
    cancer.org | 1.800.227.2345 About Ovarian Cancer Overview and Types If you have been diagnosed with ovarian cancer or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is Ovarian Cancer? Research and Statistics See the latest estimates for new cases of ovarian cancer and deaths in the US and what research is currently being done. ● Key Statistics for Ovarian Cancer ● What's New in Ovarian Cancer Research? What Is Ovarian Cancer? Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer and can spread. To learn more about how cancers start and spread, see What Is Cancer?1 Ovarian cancers were previously believed to begin only in the ovaries, but recent evidence suggests that many ovarian cancers may actually start in the cells in the far (distal) end of the fallopian tubes. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 What are the ovaries? Ovaries are reproductive glands found only in females (women). The ovaries produce eggs (ova) for reproduction. The eggs travel from the ovaries through the fallopian tubes into the uterus where the fertilized egg settles in and develops into a fetus. The ovaries are also the main source of the female hormones estrogen and progesterone. One ovary is on each side of the uterus. The ovaries are mainly made up of 3 kinds of cells. Each type of cell can develop into a different type of tumor: ● Epithelial tumors start from the cells that cover the outer surface of the ovary.
    [Show full text]
  • Primary Screening for Breast Cancer with Conventional Mammography: Clinical Summary
    Primary Screening for Breast Cancer With Conventional Mammography: Clinical Summary Population Women aged 40 to 49 y Women aged 50 to 74 y Women aged ≥75 y The decision to start screening should be No recommendation. Recommendation Screen every 2 years. an individual one. Grade: I statement Grade: B Grade: C (insufficient evidence) These recommendations apply to asymptomatic women aged ≥40 y who do not have preexisting breast cancer or a previously diagnosed high-risk breast lesion and who are not at high risk for breast cancer because of a known underlying genetic mutation Risk Assessment (such as a BRCA1 or BRCA2 gene mutation or other familial breast cancer syndrome) or a history of chest radiation at a young age. Increasing age is the most important risk factor for most women. Conventional digital mammography has essentially replaced film mammography as the primary method for breast cancer screening Screening Tests in the United States. Conventional digital screening mammography has about the same diagnostic accuracy as film overall, although digital screening seems to have comparatively higher sensitivity but the same or lower specificity in women age <50 y. For women who are at average risk for breast cancer, most of the benefit of mammography results from biennial screening during Starting and ages 50 to 74 y. While screening mammography in women aged 40 to 49 y may reduce the risk for breast cancer death, the Stopping Ages number of deaths averted is smaller than that in older women and the number of false-positive results and unnecessary biopsies is larger. The balance of benefits and harms is likely to improve as women move from their early to late 40s.
    [Show full text]
  • PCHHAX Overview of Flaxseed Patent
    Available online a t www.derpharmachemica.com ISSN 0975-413X Der Pharma Chemica, 2016, 8(14):33-38 CODEN (USA): PCHHAX (http://derpharmachemica.com/archive.html) Overview of Flaxseed Patent Applications for the prevention and treatment of human cancer Sepideh Miraj Infertility Fellowship, Medicinal Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran _____________________________________________________________________________________________ ABSTRACT Flaxseed, Linum usitatissimum, is a member of the genus Linum in the family Linaceae. It is a food and fiber crop cultivated in cooler regions of the world. The aim of this study is to overview its anti-cancer and anti-tumor effects. This review article was carried out by searching studies in PubMed, Medline, Web of Science, and IranMedex databases up to 2016.totally, of 1 08 found articles, 41 articles were included. The search terms were “Flaxseed. ”, “therapeutic”, “pharmacological”, anticancer, anti-tumor. Various studies have shown that Flaxseed. Possess Anti-Breast Cancer properties, Anti-Breast tumors properties , Anti-Ovary cancer properties, Gut-associated diseases properties, Lung tumor properties, Inflammation properties, Anti-Skin Carcinogenesis properties, Pro- carcinogenic, Mastalgia properties, Aortic remodeling ,Anti-mammary Cancer effect ,Antioxidant and Antiproliferative ,Colon cancer properties, Esophagitis properties, Apoptosis properties. Flaxseed possess lots of therapeutic and pharmacological effects.in this study, its anticancer, anti-tumor effects was overviewed. Keywords : Flaxseed, therapeutic, pharmacological, anticancer, anti-tumor. _____________________________________________________________________________________________ INTRODUCTION It is proved that herbal medicine is effective in the treatment of many diseases [1-10].Flax, Linum usitatissimum , is a member of the genus Linum in the family Linaceae. It is a food and fiber crop cultivated in cooler regions of the world.
    [Show full text]
  • Hematopoietic and Lymphoid Neoplasm Coding Manual
    Hematopoietic and Lymphoid Neoplasm Coding Manual Effective with Cases Diagnosed 1/1/2010 and Forward Published August 2021 Editors: Jennifer Ruhl, MSHCA, RHIT, CCS, CTR, NCI SEER Margaret (Peggy) Adamo, BS, AAS, RHIT, CTR, NCI SEER Lois Dickie, CTR, NCI SEER Serban Negoita, MD, PhD, CTR, NCI SEER Suggested citation: Ruhl J, Adamo M, Dickie L., Negoita, S. (August 2021). Hematopoietic and Lymphoid Neoplasm Coding Manual. National Cancer Institute, Bethesda, MD, 2021. Hematopoietic and Lymphoid Neoplasm Coding Manual 1 In Appreciation NCI SEER gratefully acknowledges the dedicated work of Drs, Charles Platz and Graca Dores since the inception of the Hematopoietic project. They continue to provide support. We deeply appreciate their willingness to serve as advisors for the rules within this manual. The quality of this Hematopoietic project is directly related to their commitment. NCI SEER would also like to acknowledge the following individuals who provided input on the manual and/or the database. Their contributions are greatly appreciated. • Carolyn Callaghan, CTR (SEER Seattle Registry) • Tiffany Janes, CTR (SEER Seattle Registry) We would also like to give a special thanks to the following individuals at Information Management Services, Inc. (IMS) who provide us with document support and web development. • Suzanne Adams, BS, CTR • Ginger Carter, BA • Sean Brennan, BS • Paul Stephenson, BS • Jacob Tomlinson, BS Hematopoietic and Lymphoid Neoplasm Coding Manual 2 Dedication The Hematopoietic and Lymphoid Neoplasm Coding Manual (Heme manual) and the companion Hematopoietic and Lymphoid Neoplasm Database (Heme DB) are dedicated to the hard-working cancer registrars across the world who meticulously identify, abstract, and code cancer data.
    [Show full text]
  • A Bibliometric Analysis
    787 Original Article Page 1 of 9 The 100 most cited articles on lung cancer screening: a bibliometric analysis Meng Li1,2, Qiang Cai2,3, Jing-Wen Ma1, Li Zhang1,2, Claudia I. Henschke2 1Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 2Department of Radiology, Mount Sinai Health System, New York, NY, USA; 3Department of Radiology, Shanxi Provincial People’s Hospital, Taiyuan, China Contributions: (I) Conception and design: M Li, CI Henschke; (II) Administrative support: CI Henschke; (III) Provision of study materials or patients: M Li, CI Henschke; (IV) Collection and assembly of data: M Li, L Zhang; (V) Data analysis and interpretation: M Li, Q Cai, JW Ma; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Claudia I. Henschke. Department of Radiology, Mount Sinai Health System, 1 Gustave Levy Place, New York, NY 10029, USA. Email: [email protected]. Background: The number of citations of an article reflects its impact on the scientific community. The aim of this study was to identify and characterize the 100 most cited articles on lung cancer screening. Methods: The 100 most cited articles on lung cancer screening published in all scientific journals were identified using the Web of Science database. Relevant data, including the number of citations, publication year, publishing journal and impact factor (IF), authorship and country of origin, article type and study design, screening modality, and main topic, were collected and analyzed. Results: The 100 most cited articles were all English and published between 1973 and 2017, with 81 published after 2000.
    [Show full text]
  • Cancer-Related Terminology Used by a Healthcare Team
    FEATURE IJPC GLossary OF THE MOST COMMON CANCER-RELated TERMINOLOGY USED BY A HEALthcare TEAM ADRENAL GLAND: Two glands, located near the kidneys, CANCER: A general term for more than 100 diseases in which ab- which produce hormones that control metabolism, fluid balance, normal cells grow out of control. Also used to refer to a malignant and blood pressure. They also produce small amounts of “male” (cancerous) tumor. hormones (androgens) and “female” hormones (estrogens and progesterone). CARCINOGEN: Any substance that causes cancer or helps cancer grow (e.g., tobacco smoke contains many carcinogens that greatly ADVANCED cancer: A general term describing later stages increase the risk of lung cancer) of cancer (usually stage 3 or 4) in which the disease has spread from the primary site (where it started) to other parts of the body. Catheter: A thin, flexible tube used to introduce fluids into the When the cancer has spread only to nearby areas, it is called locally body or to remove fluids from the body advanced. If it has spread to distant parts of the body, it is called metastatic. CELL: The basic unit of which all living things are made. Cells re- place themselves by dividing and forming new cells. The processes ALOPECIA: Hair loss, usually temporary. This is a side effect of that control the formation of new cells and the death of old cells are some chemotherapy drugs or radiation. disrupted in cancer. ANEMIA: Having too few red blood cells (“low blood”). This may CENTRAL VENOUS catheter (CVC): A special thin, flex- be a complication of the cancer or a side effect of treatment.
    [Show full text]
  • Cancer Treatment and Survivorship Facts & Figures 2019-2021
    Cancer Treatment & Survivorship Facts & Figures 2019-2021 Estimated Numbers of Cancer Survivors by State as of January 1, 2019 WA 386,540 NH MT VT 84,080 ME ND 95,540 59,970 38,430 34,360 OR MN 213,620 300,980 MA ID 434,230 77,860 SD WI NY 42,810 313,370 1,105,550 WY MI 33,310 RI 570,760 67,900 IA PA NE CT 243,410 NV 185,720 771,120 108,500 OH 132,950 NJ 543,190 UT IL IN 581,350 115,840 651,810 296,940 DE 55,460 CA CO WV 225,470 1,888,480 KS 117,070 VA MO MD 275,420 151,950 408,060 300,200 KY 254,780 DC 18,750 NC TN 470,120 AZ OK 326,530 NM 207,260 AR 392,530 111,620 SC 143,320 280,890 GA AL MS 446,900 135,260 244,320 TX 1,140,170 LA 232,100 AK 36,550 FL 1,482,090 US 16,920,370 HI 84,960 States estimates do not sum to US total due to rounding. Source: Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute. Contents Introduction 1 Long-term Survivorship 24 Who Are Cancer Survivors? 1 Quality of Life 24 How Many People Have a History of Cancer? 2 Financial Hardship among Cancer Survivors 26 Cancer Treatment and Common Side Effects 4 Regaining and Improving Health through Healthy Behaviors 26 Cancer Survival and Access to Care 5 Concerns of Caregivers and Families 28 Selected Cancers 6 The Future of Cancer Survivorship in Breast (Female) 6 the United States 28 Cancers in Children and Adolescents 9 The American Cancer Society 30 Colon and Rectum 10 How the American Cancer Society Saves Lives 30 Leukemia and Lymphoma 12 Research 34 Lung and Bronchus 15 Advocacy 34 Melanoma of the Skin 16 Prostate 16 Sources of Statistics 36 Testis 17 References 37 Thyroid 19 Acknowledgments 45 Urinary Bladder 19 Uterine Corpus 21 Navigating the Cancer Experience: Treatment and Supportive Care 22 Making Decisions about Cancer Care 22 Cancer Rehabilitation 22 Psychosocial Care 23 Palliative Care 23 Transitioning to Long-term Survivorship 23 This publication attempts to summarize current scientific information about Global Headquarters: American Cancer Society Inc.
    [Show full text]
  • Integrative Oncology from a Bibliometric Point of View T Jenny-Ann Brodin Danell
    Complementary Therapies in Medicine 52 (2020) 102477 Contents lists available at ScienceDirect Complementary Therapies in Medicine journal homepage: www.elsevier.com/locate/ctim Integrative oncology from a bibliometric point of view T Jenny-Ann Brodin Danell Department of Sociology, Umeå University, 901 87 Umeå, Sweden ARTICLE INFO ABSTRACT keywords: Objectives: The aim of this article is to analyze the development of integrative oncology from a bibliometric point Integrative oncology of view. The publication and citation patterns of publications are analyzed and their contents mapped. Complementary therapies Design: This study is based on bibliometric methods. The data sets consist of 7 025 respectively 4 990 pub- Research domain lications over the time period 1966-2016, shown in PubMed and Web of Science. Bibliometric methods Results: The expansion of the numbers of these publications took place in the late 1990s/early 2000s. Research is Citation analysis dominated by authors located in the USA, China and Germany who are working at well-established research Content analysis universities and university hospitals. The clinical share of publications is relatively small, and few studies are classified according to clinical phase. Content analysis revealed that much of the clinical research is based on surveys, and that content reflects the intersection of complementary therapies and cancer research. The latter aspect is less obvious in pre-clinical research. The most frequent journals in the material show a focus on complementary and alternative therapies or on integrative oncology, although journals focused on oncology or general/internal medicine were well-represented in the material as a whole. The most-cited publications were review articles and surveys.
    [Show full text]
  • An American Cancer Society Guide for Informed Choices Downloaded from Colleen Doyle, MS, RD; Lawrence H
    Downloaded from Nutrition and Physical Activity During and After Cancer Treatment: An American caonline.amcancersoc.org Cancer Society Guide for Informed Choices Colleen Doyle, Lawrence H. Kushi, Tim Byers, Kerry S. Courneya, Wendy Demark-Wahnefried, Barbara Grant, Anne McTiernan, Cheryl L. Rock, Cyndi Thompson, Ted Gansler, Kimberly S. Andrews and for the 2006 Nutrition, Physical Activity and Cancer Survivorship Advisory Committee CA Cancer J Clin 2006;56;323-353 DOI: 10.3322/canjclin.56.6.323 by on August 5, 2009 (©American Cancer Society, Inc.) This information is current as of August 5, 2009 The online version of this article, along with updated information and services, is located on the World Wide Web at: http://caonline.amcancersoc.org/cgi/content/full/56/6/323 To subscribe to the print issue of CA: A Cancer Journal for Clinicians, go to (US individuals only): http://caonline.amcancersoc.org/subscriptions/ CA: A Cancer Journal for Clinicians is published six times per year for the American Cancer Society by Wiley-Blackwell. A bimonthly publication, it has been published continuously since November 1950. CA is owned, published, and trademarked by the American Cancer Society, 250 Williams Street NW, Atlanta GA 30303. (©American Cancer Society, Inc.) All rights reserved. Print ISSN: 0007-9235. Online ISSN: 1542-4863. CA Cancer J Clin 2006;56:323–353 Nutrition and Physical Activity During and After Cancer Treatment: An American Cancer Society Guide for Informed Choices Downloaded from Colleen Doyle, MS, RD; Lawrence H. Kushi, ScD; Tim Byers, MD, MPH; Ms. Doyle is Director, Nutrition and Kerry S. Courneya, PhD; Wendy Demark-Wahnefried, PhD, RD, LDN; Barbara Grant, MS, Physical Activity, American Cancer Society, Atlanta, GA.
    [Show full text]
  • ACS South Atlantic Division Cancer Facts & Figures, 2007
    South Atlantic Division Cancer Facts & Figures 2007 Includes CD With State & County Data We Are Here. Making A Difference In Every Community. Delaware North Carolina District of Columbia South Carolina Georgia Virginia Maryland West Virginia South Atlantic Division, Inc. American Cancer Society Mission Statement The American Cancer Society is the nationwide, community-based, voluntary health organization dedicated to eliminating cancer as a major health problem by preventing cancer, saving lives and diminishing suffering from cancer, through research, education, advocacy, and service. Acknowledgements With grateful appreciation for their contribution and assistance: Delaware Cancer Registry Marjorie Shannon, MS District of Columbia Cancer Registry Aaron Adade, PhD Georgia Comprehensive Cancer Registry Rana Bayakly, MPH Maryland Cancer Registry Diane Dwyer, MD Maryland Vital Statistics Administration Hal Sommers, MA North Carolina Central Cancer Registry Karen Knight, MS; Chandrika Rao, PhD South Carolina Central Cancer Registry Susan Bolick-Aldrich, MSPH, CTR; Margaret Ehlers, MSPH Virginia Cancer Registry Jim Martin, PhD; Carolyn Halbert MA, MPH Virginia Center For Health Statistics Calvin Reynolds, Robert Magnotti West Virginia Cancer Registry Patricia Colsher, PhD, Myra Fernatt West Virginia Health Statistics Center Daniel Christy, MPA; Tom Light American Cancer Society Kathleen Wall, MSW Editor: Judy Walrath, PhD Planning Manager © 2007 American Cancer Society, South Atlantic Division, Inc. All rights reserved, including the right
    [Show full text]